BioVie Inc. Other Comprehensive Income (Loss), Net of Tax
BioVie Inc. (BIVI) reported Other Comprehensive Income (Loss), Net of Tax of -$176.59 thousand for the 12-month period ending 2024-06-30, per its S-1/A filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- BioVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- BioVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- BioVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-12-31 was $0.00.
- BioVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was -$176.59K.
- BioVie Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $176.59K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | -$176.59K S-1/A · filed 2026-08-06 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | -$176.59K 10-Q · filed 2025-05-12 | -$16.50K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11 | -$176.59K 10-Q · filed 2025-02-11 | -$16.50K derived: sum of 3 quarters · filed 2025-02-11 | $0.00 derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-09-30 | -$176.59K 10-Q · filed 2024-11-13 | -$16.50K derived: sum of 2 quarters · filed 2024-11-13 | $0.00 derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $160.09K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $176.59K derived: sum of 2 quarters · filed 2024-09-30 | $176.59K 10-K · filed 2024-09-30 | |
| 2023-03-31 | $16.50K 10-Q · filed 2024-05-14 | $16.50K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |